VOYAGER THERAPEUTICS INC (VYGR)
US92915B1061 - Common Stock
ChartMill assigns a Buy % Consensus number of 85% to VYGR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 17.57. This target is 210.64% above the current price.
VYGR was analyzed by 16 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about VYGR.
In the previous month the buy percentage consensus was at a similar level.
VYGR was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-16 | Leerink Partners | Initiate | Outperform |
| 2024-08-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-07-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-05-14 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-03-26 | Guggenheim | Initiate | Buy |
| 2024-03-19 | HC Wainwright & Co. | Initiate | Buy |
| 2024-03-07 | Citigroup | Initiate | Buy |
| 2024-01-02 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2023-08-07 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2023-05-10 | Truist Securities | Initiate | Buy |
| 2023-05-10 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2023-03-10 | Oppenheimer | Initiate | Outperform |
| 2021-11-03 | Chardan Capital | Maintains | Neutral |
| 2021-10-07 | Baird | Upgrade | Neutral -> Outperform |
| 2021-04-19 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-02-26 | Baird | Downgrade | Outperform -> Neutral |